Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
AIMMUNE THERAPEUTICS (AIMT)
Last aimmune therapeutics earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aimmune.com/corporate-profile
Company Research
Source: Business Wire
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. The randomized, double-blind, placebo-controlled ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success) clinical trial of AR101 will enroll approximately 160 peanut-allergic children and adolescents ages 4-17 at multiple sites in several European countries. The ARTEMIS trial follows Aimmune’s ongoing Phase 3 PALISADE trial, taking place in eight countries in Europe, the Uni
Show less
Read more
Impact Snapshot
Event Time:
AIMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIMT alerts
High impacting AIMMUNE THERAPEUTICS news events
Weekly update
A roundup of the hottest topics